Glaxosmithkline Pharmaceuticals Ltd
₹2594.40
(-2.78%)
Fri, 13 Feb 2026, 01:38 pm
Health Technology
Pharmaceuticals: Major
24.5KGlaxosmithkline Pharmaceuticals Share Price Live Chart
1 Day
0 (0%)
No Result Found
Summary
Market Cap
45179.74
Net Profit
927.58
P/B
24.98
Sector P/E
32.61
P/E
52.54
EV/EBITDA
35.66
Debt/Equity (Industry)
0.08
Interest Cover (Industry)
146.92
ROCE (Industry)
20.66
RONW (Industry)
16.60
ROE
49.75
ROCE
59.29
Debt/Equity
0.01
EPS (TTM)
59.37
Dividend Yield
2.02
Book Value
100.80
Interest Cover
962.74
Analysis
all
- Dividends per share have increased over the past 10 years.
- Dividends after 3 years are expected to be covered by earnings (1.5x coverage).
- GlaxoSmithKline Pharmaceuticals's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
- GlaxoSmithKline Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
- GlaxoSmithKline Pharmaceuticals's earnings growth is expected to exceed the India market average.
- Dividends paid are not well covered by earnings (0.3x coverage).
- Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
- GlaxoSmithKline Pharmaceuticals's dividend is below the markets top 25% of dividend payers in India (3.08%).
- Cash flow for GlaxoSmithKline Pharmaceuticals is expected to increase but not above the 50% threshold in 2 years time.
- GlaxoSmithKline Pharmaceuticals's revenue is expected to increase but not above the 50% threshold in 2 years time.
Shareholding
| Shareholders | DEC 2025 | SEPT 2025 | JUN 2025 | MAR 2025 | DEC 2024 |
|---|---|---|---|---|---|
| Promoters | 75 | 75 | 75 | 75 | 75 |
| FII | 4.64 | 4.79 | 4.88 | 4.52 | 4.50 |
| DII | 7.70 | 7.75 | 7.70 | 7.79 | 7.30 |
| Public | 12.66 | 12.45 | 12.41 | 12.69 | 13.19 |
| Government | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Technical Analysis
Support and Resistance
| Type | R3 | R2 | R1 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | - | - | - | - | - | - | - |
| Fibonacci | - | - | - | - | - | - | - |
| Camarilla | - | - | - | - | - | - | - |
Pivots Level: Classic
R3
+-
-
R2
+-
-
R1
+-
-
S1
--
-
S2
--
-
S3
--
-
Moving Average
Period
Value
10-EMA
-
20-EMA
-
30-EMA
-
50-EMA
-
100-EMA
-
200-EMA
-
Corporate Actions
| Announcement Date | Purpose | Action | Ex Date |
|---|---|---|---|
| 09 Feb 2026 | board-meetings | Quarterly Results | |
| 06 Nov 2025 | board-meetings | Quarterly Results, Half Yearly Results | |
| 13 May 2025 | agm | ||
| 13 May 2025 | dividend | ₹42.00 Dividend /Share | 30 May 2025 |
| 29 Oct 2024 | dividend | ₹12.00 Dividend /Share | 07 Nov 2024 |
| 17 May 2024 | agm | ||
| 17 May 2024 | dividend | ₹32.00 Dividend /Share | 31 May 2024 |
| 30 May 2023 | agm | ||
| 17 May 2023 | dividend | ₹32.00 Dividend /Share | 30 Jun 2023 |
| 16 May 2022 | agm |
Peer Comparison
Glaxosmithkline Pharmaceuticals Ltd
Dr Reddys Laboratories Ltd
Torrent Pharmaceuticals Ltd
Sun Pharmaceutical Industries Ltd
Cipla Ltd
Divis Laboratories Ltd
Glaxosmithkline Pharmaceuticals Ltd About
GlaxoSmithKline Pharmaceuticals is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.
Industry
Pharmaceuticals - Multinational
Founded
1924
Headquarters
CEO
Renu S Karnad
Employees
Contact
Website
http://www.gsk-india.com
askus@gsk.com; ajay.a.nadkarni@gsk.com
Phone
91-022-24959595
Location
GSK House, Dr Annie Besant Road Worli, Mumbai, Maharashtra, 400030
Glaxosmithkline Pharmaceuticals Ltd Company History
| Year | History |
|---|---|
| 2019 |
|
| 2020 |
|
| 2021 |
|
| 2022 |
|
| 2024 |
|
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800